title: Heparin antibodies and thromboembolism in heparin-coated and noncoated ventricular assist devices.
abstract: OBJECTIVE
  Coating of ventricular assist devices (VADs) with heparin improves the biocompatibility and may reduce the need for systemic anticoagulation. However, heparins are associated with the risk of formation of heparin/platelet factor 4 antibodies (HPF4/A) and the development of heparin-associated thromboemboli. We analyzed the occurrence of HPF4/A and thromboembolism in patients with heparin-coated and noncoated VADs.
  
  
  METHODS
  One hundred patients were enrolled in the investigation. Fifty-seven received a heparin-coated (group 1) and 43 a noncoated (group 2) VAD. HPF4/A testing was performed before and 2 and 12 weeks after implantation by the heparin platelet factor 4 enzyme-linked immunosorbent assay.
  
  
  RESULTS
  There was no significant difference in the occurrence of HPF4/A in the 2 groups (P =.102). Before the operation, 21 of the patients in group 1 had positive test responses and 25 in group 2. No patient had HPF4/A after termination of systemic heparinization. In group 1 there was no significant difference in the incidence of recurrent pump thromboses in patients who had positive test responses for HPF4/A (n = 11) when compared with those who had negative test responses (n = 9, P =.89). Twenty-one patients had HPF/A but no thromboembolism. However, all 22 patients who had thromboembolism had HPF4/A.
  
  
  CONCLUSIONS
  Heparin coating of the VAD surface does not enhance the occurrence of HPF4/A-associated immunologic or thrombogenic reactions. However, the presence of these antibodies is strongly associated with an increased risk of thromboembolism in patients with a VAD.
authors.affiliation: Department of Anesthesiology, Deutsches Herzzentrum Berlin, Augustenberger Platz 1, D-13353 Berlin, Germany. koster@dhzb.de
authors.forename: A
authors.initials: A
authors.lastname: Koster
authors.forename: M
authors.initials: M
authors.lastname: Loebe
authors.forename: R
authors.initials: R
authors.lastname: Sodian
authors.forename: E V
authors.initials: EV
authors.lastname: Potapov
authors.forename: R
authors.initials: R
authors.lastname: Hansen
authors.forename: J
authors.initials: J
authors.lastname: Müller
authors.forename: F
authors.initials: F
authors.lastname: Mertzlufft
authors.forename: G J
authors.initials: GJ
authors.lastname: Crystal
authors.forename: H
authors.initials: H
authors.lastname: Kuppe
authors.forename: R
authors.initials: R
authors.lastname: Hetzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000276:immunology*; D006353:Heart-Assist Devices / Q000009:adverse effects; D006493:Heparin / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010978:Platelet Factor 4 / Q000276:immunology*; D013923:Thromboembolism / Q000209:etiology* / Q000276:immunology
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010978:Platelet Factor 4; D006493:Heparin